Provided by Tiger Trade Technology Pte. Ltd.

iTeos Therapeutics

10.15
0.0000
Volume:- -
Turnover:111.74M
Market Cap:448.68M
PE:-2.17
High:10.15
Open:10.15
Low:10.15
Close:10.15
52wk High:17.63
52wk Low:4.80
Shares:44.21M
Float Shares:33.24M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6756
EPS(LYR):-3.3210
ROE:-34.97%
ROA:-18.49%
PB:0.91
PE(LYR):-3.06

Loading ...

Company Profile

Company Name:
iTeos Therapeutics
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.